(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2025 (18.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/193784 A1

(51) International Patent Classification:
A61K 31/438 (2006.01) *A61P 21/06* (2006.01)
A61K 38/26 (2006.01) *A61P 3/04* (2006.01)

(21) International Application Number:
PCT/US2025/019499

(22) International Filing Date:
12 March 2025 (12.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/564,052 12 March 2024 (12.03.2024) US

(71) Applicant: **LUMOS PHARMA, INC.** [US/US]; 4200 Marathon Boulevard, Suite 200, Austin, TX 78756 (US).

(72) Inventors: **SMITH, Roy**; 12 Shadow Lawn St, Houston, TX 77005 (US). **MCKEW, John**; 16611 Sugarland Rd, Boyds, MD 20841 (US). **THORNER, Michael**; 3101 Great Meadow Road, Dedham, MA 02026 (US).

(74) Agent: **MEGERDITCHIAN, Samuel, H.**; Gibbons P.C., One Gateway Center, Newark, NJ 07102 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2025/193784 A1

(54) **Title:** PHARMACEUTICAL FORMULATIONS FOR MAINTAINING LEAN MUSCLE MASS DURING WEIGHT LOSS TREATMENT

FIGURE 1



(57) **Abstract:** Described herein is a method for maintaining lean muscle mass during treatment with a GLP-1 receptor agonist or a dual GLP-1/GIP agonist.